dm+d

48614001

New Medicines

Ocular inflammation and pain associated with cataract surgery

Information

New formulation - repurposed medicine
Laboratorios SALVAT
Laboratorios SALVAT

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Potent topical corticosteroid, formulated in single dose vials, preservative free and in the form of a nano-emulsion.
Globally, cataracts are the leading cause of blindness, responsible for 51% of world blindness, representing 20 million people in 2010. Cataracts are a global health priority for the WHO. The prevalence increases with age. In the UK, cataracts are thought to affect around half of those aged >65 years to some degree, rising to 70% in those aged >85yrs. Surgical removal of the cataract is the only effective treatment to restore or maintain vision. Pain and inflammation are common post surgery [1].
Ocular inflammation and pain associated with cataract surgery
Topical

Evidence based evaluations